In September 2022, both Joakim Söderström and Niklas Wallett were elected to the Board of Directors of Idogen. Joakim Söderström was elected to be the Chairman of the Board, replacing Agneta Edberg. Joakim Söderström has now requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company and he will resume his role as a shareholder. In addition, Niklas Wallett has also requested to resign from the Board of Directors at his own request to resume his role as a shareholder.

Due to the above changes, the Board of Directors of Idogen has elected Agneta Edberg as new Chairman of the Board, effective from today. As consequence of these changes, the Board of Directors consists of Agneta Edberg, Chairman, Sharon Longhurst and Christina Herder, meaning that the Board of Directors retains a quorum. Proposal for election of a new Board of Directors will be submitted by the Nomination Committee in connection with the announcement of the notice of the Annual General Meeting 2023, at the latest.

" My goal has been to contribute to a more focused and cost-effective company. I am very pleased to see what has been accomplished so far as I now, due to work-related reasons, have to resign from the Board of Directors. I now hand over the responsibility with full confidence to the remaining members of the Board, who possesses a broad competence within business and drug development", says Joakim Söderström, resigning Chairman of the Board.

" We thank Joakim and Niklas for their short but valuable time in Idogen's Board of Directors. We will now proceed with undiminished enthusiasm to develop our IDO 8 program, where the first patient has already been enrolled," says Agneta Edberg, acceding Chairman of the Board.

For further information, please contact:

Agneta Edberg, Chairman, Idogen AB

Tel: +46 70555 75 18

E-post: edberg.agneta@gmail.com

Christina Herder, Acting CEO, Idogen AB

Tel: +46 70374 71 56

E-mail: christina.herder@idogen.com

Certified Adviser:
Vator Securities AB.

This information is such information as Idogen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 19:16 CET on November 1, 2022.

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company's most advanced program, IDO 8 - now entering its clinical phase - is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. For these hemophiliac patients, there is significant medical need for restoring the clinical effects of their treatment with factor VIII. This is a unique market positioning that over the long term could replace immune tolerance induction (ITI) treatments, with significant market potential. The planned IDO 8 clinical trial will validate the company's technology platform and facilitate a range of other applications in fields such as organ transplants (IDO T)  and autoimmune diseases (IDO AID).More information about Idogen is available viahttps://www.idogen.com